Glycemic and weight changes after persistent use of incident oral diabetes therapy: A veterans administration retrospective cohort study

Mary Margaret Huizinga, Christianne L. Roumie, Robert A. Greevy, Xulei Liu, Harvey J. Murff, Adriana M. Hung, Carlos G. Grijalva, Marie R. Griffin

Research output: Contribution to journalArticle

Abstract

Purpose: Systematic reviews have reported that sulfonylureas and metformin were as effective in reducing hemoglobin A1c (A1C) as other oral antidiabetic drugs (OADs) in clinical trial populations. Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI). Methods: Retrospective cohort study using data from the Veterans Affairs Mid-South network (2001-2007). Of 18-205 veterans who filled 19-511 incident OAD prescriptions, 2096 had complete covariates, persisted on their incident treatment for 12 months, and had baseline and 12 month A1C values. For the BMI analysis, 2484 patients had complete information. Incident OAD regimens included metformin and sulfonylureas. Primary outcomes were 12 month A1C and BMI, which were compared controlling for demographic characteristics, baseline A1C and BMI, psychiatric diagnoses, and healthcare utilization. Results: Median [interquartile range (IQR)] A1C decreased from 7.1% [6.5, 7.8] at baseline to 6.5% [6.0, 7.0] at 12 months. Twelve month-A1C in sulfonylurea users was similar to metformin users. The median [IQR] BMI decreased from 31.1 [27.8, 34.9] to 30.7 [27.5, 34.5] kg/m2. Sulfonylureas were associated with a significantly higher 12 month BMI than metformin (12 month adjusted mean difference: 1.05 kg/m2, 95%CI: 0.90-1.20, p <0.0001). Conclusions: These analyses support the use of metformin as first choice of OAD because of similar glycemic control but improved BMI when compared to sulfonylureas.

Original languageEnglish (US)
Pages (from-to)1108-1112
Number of pages5
JournalPharmacoepidemiology and Drug Safety
Volume19
Issue number11
DOIs
StatePublished - Nov 2010

Fingerprint

United States Department of Veterans Affairs
Hypoglycemic Agents
Metformin
Body Mass Index
Cohort Studies
Retrospective Studies
Weights and Measures
Veterans
Therapeutics
Drug Prescriptions
Mental Disorders
Population
Hemoglobins
Demography
Clinical Trials
Delivery of Health Care

Keywords

  • Comparative effectiveness
  • Diabetes
  • Oral antidiabetic agents

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Epidemiology

Cite this

Glycemic and weight changes after persistent use of incident oral diabetes therapy : A veterans administration retrospective cohort study. / Huizinga, Mary Margaret; Roumie, Christianne L.; Greevy, Robert A.; Liu, Xulei; Murff, Harvey J.; Hung, Adriana M.; Grijalva, Carlos G.; Griffin, Marie R.

In: Pharmacoepidemiology and Drug Safety, Vol. 19, No. 11, 11.2010, p. 1108-1112.

Research output: Contribution to journalArticle

Huizinga, Mary Margaret ; Roumie, Christianne L. ; Greevy, Robert A. ; Liu, Xulei ; Murff, Harvey J. ; Hung, Adriana M. ; Grijalva, Carlos G. ; Griffin, Marie R. / Glycemic and weight changes after persistent use of incident oral diabetes therapy : A veterans administration retrospective cohort study. In: Pharmacoepidemiology and Drug Safety. 2010 ; Vol. 19, No. 11. pp. 1108-1112.
@article{e149c453dde742e29dc00007faddd40d,
title = "Glycemic and weight changes after persistent use of incident oral diabetes therapy: A veterans administration retrospective cohort study",
abstract = "Purpose: Systematic reviews have reported that sulfonylureas and metformin were as effective in reducing hemoglobin A1c (A1C) as other oral antidiabetic drugs (OADs) in clinical trial populations. Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI). Methods: Retrospective cohort study using data from the Veterans Affairs Mid-South network (2001-2007). Of 18-205 veterans who filled 19-511 incident OAD prescriptions, 2096 had complete covariates, persisted on their incident treatment for 12 months, and had baseline and 12 month A1C values. For the BMI analysis, 2484 patients had complete information. Incident OAD regimens included metformin and sulfonylureas. Primary outcomes were 12 month A1C and BMI, which were compared controlling for demographic characteristics, baseline A1C and BMI, psychiatric diagnoses, and healthcare utilization. Results: Median [interquartile range (IQR)] A1C decreased from 7.1{\%} [6.5, 7.8] at baseline to 6.5{\%} [6.0, 7.0] at 12 months. Twelve month-A1C in sulfonylurea users was similar to metformin users. The median [IQR] BMI decreased from 31.1 [27.8, 34.9] to 30.7 [27.5, 34.5] kg/m2. Sulfonylureas were associated with a significantly higher 12 month BMI than metformin (12 month adjusted mean difference: 1.05 kg/m2, 95{\%}CI: 0.90-1.20, p <0.0001). Conclusions: These analyses support the use of metformin as first choice of OAD because of similar glycemic control but improved BMI when compared to sulfonylureas.",
keywords = "Comparative effectiveness, Diabetes, Oral antidiabetic agents",
author = "Huizinga, {Mary Margaret} and Roumie, {Christianne L.} and Greevy, {Robert A.} and Xulei Liu and Murff, {Harvey J.} and Hung, {Adriana M.} and Grijalva, {Carlos G.} and Griffin, {Marie R.}",
year = "2010",
month = "11",
doi = "10.1002/pds.2035",
language = "English (US)",
volume = "19",
pages = "1108--1112",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Glycemic and weight changes after persistent use of incident oral diabetes therapy

T2 - A veterans administration retrospective cohort study

AU - Huizinga, Mary Margaret

AU - Roumie, Christianne L.

AU - Greevy, Robert A.

AU - Liu, Xulei

AU - Murff, Harvey J.

AU - Hung, Adriana M.

AU - Grijalva, Carlos G.

AU - Griffin, Marie R.

PY - 2010/11

Y1 - 2010/11

N2 - Purpose: Systematic reviews have reported that sulfonylureas and metformin were as effective in reducing hemoglobin A1c (A1C) as other oral antidiabetic drugs (OADs) in clinical trial populations. Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI). Methods: Retrospective cohort study using data from the Veterans Affairs Mid-South network (2001-2007). Of 18-205 veterans who filled 19-511 incident OAD prescriptions, 2096 had complete covariates, persisted on their incident treatment for 12 months, and had baseline and 12 month A1C values. For the BMI analysis, 2484 patients had complete information. Incident OAD regimens included metformin and sulfonylureas. Primary outcomes were 12 month A1C and BMI, which were compared controlling for demographic characteristics, baseline A1C and BMI, psychiatric diagnoses, and healthcare utilization. Results: Median [interquartile range (IQR)] A1C decreased from 7.1% [6.5, 7.8] at baseline to 6.5% [6.0, 7.0] at 12 months. Twelve month-A1C in sulfonylurea users was similar to metformin users. The median [IQR] BMI decreased from 31.1 [27.8, 34.9] to 30.7 [27.5, 34.5] kg/m2. Sulfonylureas were associated with a significantly higher 12 month BMI than metformin (12 month adjusted mean difference: 1.05 kg/m2, 95%CI: 0.90-1.20, p <0.0001). Conclusions: These analyses support the use of metformin as first choice of OAD because of similar glycemic control but improved BMI when compared to sulfonylureas.

AB - Purpose: Systematic reviews have reported that sulfonylureas and metformin were as effective in reducing hemoglobin A1c (A1C) as other oral antidiabetic drugs (OADs) in clinical trial populations. Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI). Methods: Retrospective cohort study using data from the Veterans Affairs Mid-South network (2001-2007). Of 18-205 veterans who filled 19-511 incident OAD prescriptions, 2096 had complete covariates, persisted on their incident treatment for 12 months, and had baseline and 12 month A1C values. For the BMI analysis, 2484 patients had complete information. Incident OAD regimens included metformin and sulfonylureas. Primary outcomes were 12 month A1C and BMI, which were compared controlling for demographic characteristics, baseline A1C and BMI, psychiatric diagnoses, and healthcare utilization. Results: Median [interquartile range (IQR)] A1C decreased from 7.1% [6.5, 7.8] at baseline to 6.5% [6.0, 7.0] at 12 months. Twelve month-A1C in sulfonylurea users was similar to metformin users. The median [IQR] BMI decreased from 31.1 [27.8, 34.9] to 30.7 [27.5, 34.5] kg/m2. Sulfonylureas were associated with a significantly higher 12 month BMI than metformin (12 month adjusted mean difference: 1.05 kg/m2, 95%CI: 0.90-1.20, p <0.0001). Conclusions: These analyses support the use of metformin as first choice of OAD because of similar glycemic control but improved BMI when compared to sulfonylureas.

KW - Comparative effectiveness

KW - Diabetes

KW - Oral antidiabetic agents

UR - http://www.scopus.com/inward/record.url?scp=78049265356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049265356&partnerID=8YFLogxK

U2 - 10.1002/pds.2035

DO - 10.1002/pds.2035

M3 - Article

C2 - 20878643

AN - SCOPUS:78049265356

VL - 19

SP - 1108

EP - 1112

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 11

ER -